N-(3-(trifluoromethyl)phenyl) acrylamide | 1794-20-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-(3-(trifluoromethyl)phenyl) acrylamide
• 英文别名: N-[3-(trifluoromethyl)phenyl]prop-2-enamide
• CAS: 1794-20-3
• 化学式: C₁₀H₈F₃NO
• mdl: MFCD00587328
• 分子量: 215.175
• InChiKey: AVBCENRBHWYZKE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-丁炔酸乙酯 、 N-(3-(trifluoromethyl)phenyl) acrylamide 在 Oxone 、 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 、 potassium acetate 作用下， 以 1,4-二氧六环 为溶剂， 反应 30.0h， 以47%的产率得到ethyl 2-methyl-6-oxo-1-(3-(trifluoromethyl)phenyl)-1,6-dihydropyridine-3-carboxylate
  参考文献：
  名称：

  丙烯酰胺与2-炔酸酯的Ru催化区域选择性级联环化反应，用于合成各种6-氧代烟酸酯

  摘要：

  描述了Ru催化的丙烯酰胺与2-炔酸酯通过氮杂-Michael / CH活化序列合成的6-氧代烟酸酯的区域选择性级联环化反应。通过进行相应的6-氧代烟酸的银介导的原脱羧以提供2-吡啶酮，已经证实了该方案的区域选择性。所开发的方案不含铜或银盐，并使用廉价，安全且对环境无害的基于过氧化物的“氧酮”作为唯一氧化剂。还演示了该协议的氧化还原中性版本。

  DOI：

  10.1021/acs.joc.8b02783
• 作为产物：
  描述：

  间氨基三氟甲苯 、 丙烯酰氯 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 N-(3-(trifluoromethyl)phenyl) acrylamide
  参考文献：
  名称：

  N-芳基丙烯酰胺的谷胱甘肽（GSH）反应性的系统研究：1.芳基取代的影响

  摘要：

  靶向共价抑制剂的设计成功与否，部分取决于对亲电试剂反应性影响因素的了解。为了进一步了解N-芳基丙烯酰胺之间的结构-反应关系，我们确定了在11个不同的邻位，间位和对位独立取代的N-芳基丙烯酰胺家族的谷胱甘肽（GSH）反应速率抑制剂设计的共同点。我们发现，取代基对反应速率的影响表明邻位，间位和对位取代具有线性Hammett相关性。此外，我们注意到1 H和13之间的相关性丙烯酰胺与GSH反应速率的C NMR化学位移，表明NMR化学位移可能是相对丙烯酰胺反应性的便捷替代量度。密度泛函理论计算揭示了计算的活化参数与实验确定的反应速率之间的相关性，从而验证了这种方法以预期方式筛选合成候选物的应用。

  DOI：

  10.1021/acs.jmedchem.5b01018

文献信息

• Phosphinic acids
  申请人：Hilpert Hans

  公开号：US20050107341A1

  公开（公告）日：2005-05-19

  The present invention relates to phosphinic acid derivatives of formula I wherein R 1 , R 2 , R 3 and R 4 are described hereinabove. These compounds can be used in the treatment or prevention of a disease related to the inhibition of β-secretase, inter alia for the treatment of Alzheimer's disease.

  本发明涉及式I的膦酸衍生物，其中R1、R2、R3和R4如上所述。这些化合物可用于治疗或预防与β-分泌酶抑制有关的疾病，包括治疗阿尔茨海默病。
• 1-2-(Pyridinyl)piperazine derivatives with antianaphylactic, antibronchospastic and mast cell stabilizing activities
  作者：Alberto Catto、Gianni Motta、Alberto Tajana、Pietro Cazzulani、Dante Nardi、Amedeo Leonardi

  DOI：10.1021/jm00384a002

  日期：1987.1

  New 1-(2-pyridinyl)piperazine derivatives were synthesized and tested as inhibitors of the reaginic passive cutaneous anaphylaxis in the rat (PCA), of the histamine-induced bronchospasm in the guinea pig, and of the rat mesenteric mast cell degranulation induced by compound 48/80. On the basis of test results, a series of N-(substituted phenyl)-omega-[4-(2-pyridinyl)-1-piperazinyl]alkanamides was prepared. The nature of substituents at the anilide ring strongly influenced mast cell stabilizing activity, whereas it was less determining in the case of the other two tests. No clear correlation between the most common physicochemical parameters (pi, sigma, Vw volume) of substituents and activity could be detected. With regard to the position of substituents at the anilide ring, the rank order of potency, in the PCA and bronchoconstriction tests, was para greater than meta greater than ortho. Introduction of substituents in the 1-(2-pyridinyl)piperazinyl moiety of the N-(substituted phenyl)propanamide derivatives hardly affected activity, or the effect was deleterious. Some of the new compounds exhibited a simultaneous remarkable activity in all the three assays employed.
• A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia
  作者：Nagore I. Marín-Ramos、Moisés Balabasquer、Francisco J. Ortega-Nogales、Iván R. Torrecillas、Ana Gil-Ordóñez、Beatriz Marcos-Ramiro、Pedro Aguilar-Garrido、Ian Cushman、Antonio Romero、Francisco J. Medrano、Consuelo Gajate、Faustino Mollinedo、Mark R. Philips、Mercedes Campillo、Miguel Gallardo、Mar Martín-Fontecha、María L. López-Rodríguez、Silvia Ortega-Gutiérrez

  DOI：10.1021/acs.jmedchem.9b00145

  日期：2019.7.11

  Blockade of Ras activity by inhibiting its post-translational methylation catalyzed by isoprenylcysteine carboxylmethyltransferase (ICMT) has been suggested as a promising antitumor strategy. However, the paucity of inhibitors has precluded the clinical validation of this approach. In this work we report a potent ICMT inhibitor, compound 3 [UCM-1336, IC50 = 2 mu M], which is selective against the other enzymes involved in the post-translational modifications of Ras. Compound 3 significantly impairs the membrane association of the four Ras isoforms, leading to a decrease of Ras activity and to inhibition of Ras downstream signaling pathways. In addition, it induces cell death in a variety of Ras-mutated tumor cell lines and increases survival in an in vivo model of acute myeloid leukemia. Because ICMT inhibition impairs the activity of the four Ras isoforms regardless of its activating mutation, compound 3 surmounts many of the common limitations of available Ras inhibitors described so far. In addition, these results validate ICMT as a valuable target for the treatment of Ras-driven tumors.
• CATTO A.; MOTTA G.; TAJANA A.; CAZZULANI P.; NARDI D.; LEONARDI A., J. MED. CHEM., 30,(1987) N 1, 13-19
  作者：CATTO A.、 MOTTA G.、 TAJANA A.、 CAZZULANI P.、 NARDI D.、 LEONARDI A.

  DOI：——

  日期：——
• PHOSPHINIC ACID DERIVATIVES, BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP1685142A1

  公开（公告）日：2006-08-02